Myocardial Infarction Treatment Market By Product Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Myocardial Infarction Treatment Market
Myocardial Infarction Treatment Market: By Product Type (Analgesics, Antiplatelet Agents, Others), By Distribution Channel (Hospitals, Hospital Pharmacies, Drug Stores, Others) & By Region-Forecast (2016-2021)
Report Code : HCR 0324
Updated Date: 23 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Myocardial Infarction Treatment surgeries are done to address the root cause of blockage of one of the coronary arteries, remove blockage of arteries, and others.  They are part of the minimal invasive surgeries for restoring the flow of blood to the other part of the arteries where the blood clot prevented the flow of oxygenated blood. Globally, increasing incidence of coronary artery disease and changes in lifestyle, increasing number of smokers, increasing incidence of obesity and lack of exercise are the prime growth drivers of global Myocardial Infarction Treatment market. In addition, increase in adoption of Myocardial Infarction Treatment in emerging economies such as China, India and others, will create new opportunities for global Myocardial Infarction Treatment market. However, higher cost of the research and development, and limited R&D Activities are the key restraints for global Myocardial Infarction Treatment market.

 Myocardial Infarction Treatment Market

Geographically North America dominated global Myocardial Infarction Treatment market, owing to expanding aging population and prevalence of co-morbidities. European is projected to have fastest growth, owing to rapidly increasing healthcare expenditure, modernization of healthcare infrastructure. Growing medical tourism industry in developing nations such as Japan, and India in this Asia Pacific is also driving the market in the region. Among all the distribution channel, hospitals has the highest market share in global Myocardial Infarction Treatment market.

This report identifies the global Myocardial Infarction Treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global Myocardial Infarction Treatment market.

This report segments global Myocardial Infarction Treatment market on the basis of product type, distribution channel, and regional market as follows:
  • Myocardial Infarction Treatment Market, By Type: Analgesics. Antiplatelet agents, and Others
  • The report has focused study on Myocardial Infarction Treatment market by basis of end-user such as: Hospitals, Hospital Pharmacies, Drug Stores, and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region

This report identifies all the major companies operating in the Myocardial Infarction Treatment market. Some of the major companies’ profiles in detail are as follows:
  • Novartis N.V
  • Daiichi Sankyo Company Limited
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • AstraZeneca Terumo Interventional Systems Inc.

1. Myocardial Infarction Treatment Market – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
   3.3. Product Benchmarking
   3.4. End User Profiling
   3.5. Top 5 Financials Analysis
4. Myocardial Infarction Treatment Market– Market Forces
   4.1. Drivers
      4.1.1. Increasing incidence of coronary artery disease and changes in lifestyle
      4.1.2. Increasing number of smokers, increasing incidence of obesity and lack of exercise
   4.2. Restraints
      4.2.1. Limited R&D activities
   4.3. Opportunities
      4.3.1. Emerging economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Myocardial Infarction Treatment Market– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Myocardial Infarction Treatment Market, By Product Type
   6.1. Analgesics
   6.2. Antiplatelet Agents
   6.3. Vasodilators
   6.4. Thrombolytics and anti-thrombotic agents
   6.5. Glycoprotein IIb/IIIa inhibitors
   6.6. B adrenergic blockers
   6.7. Angiotensin receptor antagonists
   6.8. Plaque Modification Device
   6.9. Angiotensin converting enzyme inhibitors
7. Myocardial Infarction Treatment Market, By Distribution Channel
   7.1. Hospitals
   7.2. Hospital Pharmacies
   7.3. Drug Stores
   7.4. Online Drug Stores
8. Myocardial Infarction Treatment Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Myocardial Infarction Treatment – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   10.1. Novartis N.V
   10.2. Daiichi Sankyo Company Limited
   10.3. Bristol-Myers Squibb Company
   10.4. Boehringer Ingelheim GmbH
   10.5. AstraZeneca
   10.6. Apotex Inc
   10.7. Sandoz
   10.8. Par Pharmaceutical Companies, Inc
   10.9. Mylan N.V
   10.10. Pfizer Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports